CARE Ratings has downgraded Themis Medicare Ltd’s bank facilities, citing a significant decline in operating income and sharp contraction in margins. The company reported a 15.34% revenue drop and deep operating losses, pressured by high receivables and an elongated working capital cycle. While management has leveraged asset sales to support liquidity, the downgrade to sub-investment grade status signals caution for investors tracking the company's financial recovery.
Themis Medicare Credit Rating Downgraded
Long-term bank facilities downgraded to CARE BB+ Stable; short-term facilities to CARE A4+.
Reader Takeaway: Cost-cutting and asset sales offer liquidity, but sustained operating losses and thin margins remain major pressures.
What just happened
CARE Ratings has downgraded the bank facilities of Themis Medicare, moving its long-term credit profile from investment grade (BBB-) to speculative grade (BB+). The agency noted a significant deterioration in both operational performance and debt servicing capability during the last financial year.
Why this matters
A credit downgrade typically impacts a company’s cost of borrowing and reflects heightened risk for lenders. For investors, the move highlights that Themis Medicare is struggling with a sharp decline in profitability, with the PBILDT margin collapsing to 0.79% in FY26 from 12.43% in the previous year.
The backstory
The company faced significant headwinds in FY26 as total operating income dropped by over 15% to Rs 344.58 crore. Financial pressure was further aggravated in Q1FY27, where the company reported an operating loss of Rs 51.43 crore. This was driven by a combination of one-time adjustments, including provisions for doubtful debts and a correction in institutional billing practices.
Risks to watch
Operations have become increasingly working capital intensive, with the operating cycle stretching to 230 days. The company's interest coverage ratio has also plummeted, underscoring the strain on its ability to meet debt obligations. Execution risk remains high as the firm attempts to navigate stiff market competition while simultaneously undergoing internal cost-rationalization measures.
Context metrics
- Operating Cycle: Increased to 230 days in FY26 (vs 196 days in FY25).
- Interest Coverage Ratio: Declined to 0.26x (vs 5.04x in FY25).
- Gearing: Overall gearing remains manageable at 0.36x as of March 31, 2026.
What to track next
Investors should monitor upcoming quarterly results for signs of sustained recovery in margins. The effectiveness of the management's cost-cutting strategy and the company's ability to normalize its working capital cycle will be critical for any potential future rating upgrade.